Evidence map›Paper›PMID 42123685›Full record

ArticleInternational journal of molecular sciences2026

MERS-Mpro Predictor: A Machine Learning-Based Tool for Rapid Screening of Potential MERS-CoV Main Protease Inhibitors.

Mebarka Ouassaf, Bader Y Alhatlani

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mebarka OuassafGroup of Computational and Medicinal Chemistry, LMCE Laboratory, University of Biskra, Biskra 07000, Algeria.ORCID 0000-0002-0292-0949
Bader Y AlhatlaniUnit of Scientific Research, Applied College, Qassim University, Buraydah 52571, Saudi Arabia.ORCID 0000-0003-0871-6313

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) remains a significant global health concern due to the absence of approved antiviral therapeutics. In this study, we developed a ligand-based machine learning framework to identify potential inhibitors of the MERS-CoV main protease (Mpro) using molecular representations derived from SMILES strings. Multiple classification algorithms, including logistic regression, support vector machines, random forests, and Extreme Gradient Boosting (XGBoost), were systematically evaluated. Model performance was assessed through both internal validation and an external dataset. While several models exhibited strong performance during validation, the Random Forest classifier demonstrated the most robust and consistent generalization, achieving superior predictive performance on the external dataset. To ensure model reliability, a comprehensive validation strategy was implemented, including strict data partitioning to prevent structural overlap, Y-scrambling analysis to eliminate chance correlations, and applicability domain assessment to define the model's reliable prediction space. The final model was deployed as an interactive web-based application, enabling rapid virtual screening of compounds through single or batch SMILES input, and providing activity predictions along with probability scores and selected physicochemical descriptors. Overall, this study presents a reproducible ligand-based approach for supporting the early-stage identification of potential MERS-CoV Mpro inhibitors.

Indexed as

Antiviral AgentsMachine LearningMiddle East Respiratory Syndrome CoronavirusProtease InhibitorsBoosting Machine Learning AlgorithmsClassification AlgorithmsCoronavirus InfectionsHumansLigandsPrediction AlgorithmsPredictive Learning ModelsRandom ForestSupport Vector MachineAntiviral AgentsLigandsProtease Inhibitorsdrug discoveryexternal validationmachine learningmain protease (Mpro)MERS-CoVrandom forest

Identifiers

PMID42123685
PMCPMC13163357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.